Loading, Please Wait...
RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host its Investor Day 2019 on Wednesday, March 6 in New York City, beginning at 8:00 a.m. ET and concluding at approximately 10:30 a.m. ET.
The G1 management team will provide a comprehensive overview of the company’s three clinical development programs and outline the commercialization strategy for its lead product candidate, trilaciclib. Jeffrey Crawford, M.D., Co-director, Solid Tumor Therapeutics Program, Duke Cancer Institute, will review the consequences of chemotherapy-related myelosuppression. Lowell Hart, M.D., Scientific Director of Research, Florida Cancer Specialists and trilaciclib clinical trial investigator, will discuss his clinical experience in treating cancer patients and the potential role of trilaciclib in the oncology treatment paradigm.
About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs, trilaciclib, lerociclib and G1T48, that are designed to enable more effective combination treatment strategies and improve patient outcomes across multiple oncology indications. G1 also has an active discovery program focused on cyclin-dependent kinases targets.
G1 is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
Head of Investor Relations/Public Relations